ClinicalTrials.gg
CompletedNCT06670352Updated May 28, 2026

Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

A Phase 2 interventional study of Placebo and HSK39297 50mgBID in IgA Nephropathy (IgAN), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Glomerulonephritis, IGA with a site in China — 58 open to participants now, 73 under way, 20 of them phase 3. Glomerulonephritis, IGA · China.

Enrollment
53rd of 109
87 · median 84
Started
2024
with 11 others
Phase 2
27 of 127
14 open now
Registered
74th of 127
by date

Among the 127 studies in Glomerulonephritis, IGA with a site in China, this one is the 53rd largest by enrollment of the 109 interventional ones that give a count, is one of 12 that started in 2024, is one of 27 in phase 2, and was the 74th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

58 of the 127 studies in Glomerulonephritis, IGA with a site in China are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Glomerulonephritis, IGA with a site in China, or all of them as a file.
02

Study summary

Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN

03

Conditions studied

  • IgA Nephropathy (IgAN)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must have signed and dated an IRB/IEC approved written form.Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, tumor , and other requirements of the study.
  2. Female and male patients above 18 years of age.
  3. Patients must weigh at least 35 kg to participate in the study, and must have a (BMI) below 35 kg/m2. BMI = Body weight (kg) / [Height (m)]2
  4. Subjects with a biopsy-verified IgA nephropathy and where the biopsy was performed within the prior five years.
  5. Urine protein ≥0.75g/24hr or FMV UPCR≥0.8g/g at screening.
  6. Measured (GFR) or estimated GFR (using the CKD-EPI formula 2021) ≥30 mL/min per 1.73 m2.

Exclusion criteria

Exclusion Criteria:

  1. Use of other drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 90 days, whichever is longer.
  2. All transplanted patients (any organ, including bone marrow).
  3. History of of any organ system (other than localized basal cell carcinoma of the skin or in-situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or .
  4. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the study.
  5. Pregnant or nursing (lactating) women.
  6. Plasma donation (≥ 400mL) within 12 weeks prior to first dosing.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
87 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    HSK39297 50mg BID

    Drug: HSK39297 50mgBID

  • Experimental
    HSK39297 100mg BID

    Drug: HSK39297 100mgBID

  • Experimental
    HSK39297 200mg QD

    Drug: HSK39297 200mgQD

Interventions

06

What researchers measure

Primary outcomes

  1. The ratio of 24-hour urine protein to creatinine (24h-UPCR) compared to baseline after 12 weeks of treatment

    Time frame: From week 1 to week 12

Secondary outcomes

  1. The ratio of 24-hour urine protein to creatinine (24h-UPCR) compared to baseline after 24 weeks of treatment

    Time frame: From week 1 to week 24

  2. The ratio of 24h-UPCR compared to baseline at each clinical visit point during the treatment period

    Time frame: From week 1 to week 24

  3. The ratio of 24-hour urine protein (24h-UPE) compared to baseline at each clinical visit point during the treatment period

    Time frame: From week 1 to week 24

  4. The change in estimated glomerular filtration rate (eGFR, CKD-EPI 2021 formula) compared to baseline at each clinical visit point during the treatment period

    Time frame: From week 1 to week 24

  5. The change in blood creatinine compared to baseline at each clinical visit point during the treatment period

    Time frame: From week 1 to week 24

  6. The ratio of FMV UPCR, urinary albumin to creatinine ratio (UACR) compared to baseline at each clinical visit point during the treatment period

    Time frame: From week 1 to week 24

  7. The change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale score compared to baseline at each clinical visit point during the treatment period

    0-52, the higher the score, the better the QOL.

    Time frame: From week 1 to week 24

  8. Incidence , severity and relationship of adverse events during the study period

    Time frame: From week 1 to week 24

  9. Plasma Pharmacokinetics (PK) of Time to Maximum Concentration at Steady State (Tmax,ss) of HSK39297

    Time frame: From week 1 to week 24

  10. Plasma Pharmacokinetics (PK) of Area Under the Curve at Steady State (AUCtau,ss and AUClast,ss) of HSK39297

    Time frame: From week 1 to week 24

  11. Plasma Pharmacokinetics (PK) of Pre-dose Trough at Steady State (Ctrough,ss) of HSK39297

    Time frame: From week 1 to week 24

  12. Plasma Pharmacokinetics (PK) of Maximum Concentrations (Cmax,ss) at Steady State of HSK39297

    Time frame: From week 1 to week 24

  13. Changes in alternative pathway (AP) complement activity compared to baseline at each clinical visit point during the treatment period

    Time frame: From week 1 to week 24

  14. Changes in plasma Bb levels compared to baseline at each clinical visit point during the treatment period

    Time frame: From week 1 to week 24

  15. Changes in plasma and urine sC5b-9 levels compared to baseline at each clinical visit point during the treatment period

    Time frame: From week 1 to week 24

07

Study locations

2 sites
  • Peking University First Hospital
    Beijing, Beijing Municipality 100034, China
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu 210000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Dec 2025, 14 months.

Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2024
First posted
Nov 1, 2024
StartActual
Oct 12, 2024
Primary completionActual
Dec 20, 2025
CompletionActual
May 15, 2026
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06670352
Responsible party
Sponsor
First posted
Nov 1, 2024
Start date
Oct 12, 2024
Primary completion
Dec 20, 2025
Completion
May 15, 2026
Last update
May 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK39297

Start the discussion